11 January 2007

pick of tomarrow

one can take postion in i-flex ftu and in hcl ftu bajaj auto is also looking charming

by erectusplus at 16:57:00 | 0 comments (create) - (View)

10 January 2007

INFOSYS


Buy infosys it will beat street expectation. We will strongly recomended infy with a full of confidence no daoubt doller rate is decrecess it will also slide for next 2 months but we infosys have good billing rate and heavy cash reserves in its kity no need to woory about it . in my last post i mentioned about the tulip it services we also recomended tulip it it will also beat the market expections . According to ur sources one can also take postion in tcs wipro and in saytam both will move the nifty up in short span of time .
According to our estimates Infosys' net profit will be up 8.98% from Rs 1000 crore to Rs 983.45 crore and the revenues to rise 8.03% from Rs 3651 crore to Rs 3893.89 crore.

by erectusplus at 16:23:00 | 0 comments (create) - (View)

7 January 2007


IT services and business process outsourcing (BPO) exports from India are likely to report about 26% growth to log $33.4 billion in 2007 as against $26.5 billion in 2006.
This includes revenues from captive operations, MNCs & Indian pure play third party service providers. According to projections by consulting firm NeoIT, the software and related services exports are likely to post $20.8 billion in 2007 against $17.1 billion in 2006, a growth of 21.6%. The BPO space is predicted to grow at a faster rate of 34% to gross $12.6 billion in 2007 compared to $9.4 billion last year. " Analysts tracking the sector feel that the current trend of breaking large deals into smaller contracts between several players will continue this year as new battle-lines are drawn in the $100-500 million deal space. According to Forrester, the focus would shift from cost and technology to business outcomes


So one can pick midcap it stocks who main revenue comes from bpo business nuclues softwear who is going to expand its bussiness in japan and europe is good pick at current level, patni comp , hcl technology infotec enterprices and tulip it we recomanded at current levels and in big boys we like infosys saytam wipro tcs

by erectusplus at 08:15:00 | 0 comments (create) - (View)

6 January 2007

Biocon



2002-The Biocon India group promoter of Biocon India Ltd. Ms Kiran Mazumdar Shaw, Chairman and Managing Director of Biocon India Group.

2002-Biocon India appointed DSP Merrill Lynch and Kotak Mahindra for its Rs 150-crore IPO scheduled for June next year. Biocon-Shantha Biotech, the 50:50 joint venture between Biocon India and Shantha Biotechnics, focuses on the domestic and global human insulin markets by maximizing on R&D manufacturing and regulatory capacities of the two companies.

2003

-ICICI Venture offloads 10-pc stake in Biocon

2004

-Clinigene International inaugurates human pharmacology unit for clinical trials

-Comes out with an Initial Public Offering (IPO) of 10 million shares at a price of Rs 315 per share for a face value of Rs 5 per share which constitutes 10% of the post-issue capital (Rs 100 crore), listed at Rs 425

-Biocon Ltd has entered into a nine-year export contract with US major Bristol-Myers Squibb Co to supply the bulk form of its recombinant human insulin

-Biocon forays into lifestyle drugs market

-Biocon's clinical research arm, Clinigene International Pvt Ltd. re-accredited by the College of American Pathologists (CAP) following a recent inspection

-Biocon Ltd has informed that in an unusual commercial transaction between Cuba and USA, a Californian Biotechnology Company, CancerVax Corporation received a rare US Government approval to License three experimental cancer drugs from a leading Cuban Institute (CIMAB)

-Biocon said on July 26 that its Cuban partner CIMAB (Centre for Molecular Immunology) in the joint venture with Biocon Biopharmaceuticals will be able to license out three experimental cancer drugs to a Californian Biotechnology company, CancerVax Corporation

-Biocon, Syngene enters into Research Agreement with Novartis Institutes for Biomedical Research Inc

-Biocon unveils new bio insulin

2005

Biocon signs MoU with Karolinska Institute.

-Ms Kiran Mazumdar-Shaw, CMD of Biocon Ltd, has been honoured with the Corporate Leadership Award 2005 of the American India Foundation (AIF)

-Biocon signs Licensing agreement with Bentley Pharmaceuticals Inc.

2006

-Biocon ties up with ICICI Prudential Life Insurance

-Biocon concludes Phase-IV trials of Insugem



Biocon Ltd has announced the Company and Abu Dhabi based pharmaceutical company Neopharma have signed an MOU to establish a JV to manufacture and market a range of Bio-pharmaceuticals for the GCC countries (Gulf Cooperation Council).
This landmark agreement between the two companies heralds the region's first foray to develop and market life saving biopharmaceutical products.
Dr Kiran Mazumdar-Shaw, Chairman and Managing Director, of the Company said, "The GCC region is an important market for Biocon and the JV with Neopharma is an important milestone for Biocon's global foray. Neopharma has established a world class manufacturing facility for finished formulations which was inaugurated by President APJ Abdul Kalam in 2003".
The JV will leverage the leadership position that Neopharma commands in the region under the leadership of Dr B R Shetty and expand Neopharma's existing portfolio with a range of the Company's generic and novel therapeutics that encompass Diabetes, CVS, Oncology, Auto-immune and Immunosuppressive drugs.

THE STOCK is not running from lasyt 2 year many funds and trraders and fill lo0king this counter with full opf confidence one can must have delivery of biocon one can get 50 to 60% grouth in this fyo7

by erectusplus at 11:55:00 | 0 comments (create) - (View)

5 January 2007

Level of nifty

Today market is very choppy falis to cross the upper band of4035 the good support of nifty is around 3990 and if nifty breakes3967 tahn exit from nifty many chances of nifty to touch 3900 one can have some puts of 3900 we have bulish on market our trag of nifty is 4136 tahn 4156

by erectusplus at 14:59:00 | 0 comments (create) - (View)

ranbaxy


Ranbaxy is today did well in this choppy market one can also take postion in ranbaxy with atrg of 432 and take stoploss of 408 ranbaxy is looking good at chart buy the stock is driven by news some delivery base buying is seen in this counter one can buy in equity and in future

by erectusplus at 11:30:00 | 0 comments (create) - (View)

gujrat ambuja


Gujarat Ambuja Cementsis quoting at Rs 139, down Rs 3.7, or 2.59%. It has touched an intraday high of Rs 143.50 and an intraday low of Rs 138.50. It is trading with volumes of 1,91,034 shares. Yesterday the share closed down 1.55% or Rs 2.25 at Rs 142.70. one can take postion in gujrat ambuja with atrg of 158

by erectusplus at 11:24:00 | 0 comments (create) - (View)